**Nerve Conduction Studies**

**Adjudication Guideline**

Rule Category:

Billing

**Approved by:**

Daman

Ref: No:

2016-BR-0004

Responsible:   
Medical Standards

& Research

Version Control:

Version No. V2.0

Related Adjudication Guidelines: NA

Effective Date:

22-09-2016

Last Update:

30-10-2023

Table of Contents

[1. Abstract 2](#_Toc128554276)

[1.1 For Members 2](#_Toc128554277)

[1.2 For Medical Professionals 2](#_Toc128554278)

[2. Scope 2](#_Toc128554279)

[3. Adjudication Policy 3](#_Toc128554280)

[3.1 Eligibility / Coverage Criteria 3](#_Toc128554281)

[3.2 Requirements for Coverage 3](#_Toc128554282)

[3.3 Non-Coverage 3](#_Toc128554283)

[3.4 Payment and Coding Rules 3](#_Toc128554284)

[4. Denial codes 3](#_Toc128554285)

[5. Appendices 3](#_Toc128554286)

[5.1 References 3](#_Toc128554287)

[5.2 Revision History 3](#_Toc128554288)

# Abstract

## For Members

Nerve conduction studies are performed to assess the integrity and diagnose diseases of the Peripheral nervous system. Pathological findings include conduction slowing, conduction block, no response, and/or low amplitude response.

## For Medical Professionals

This adjudication rule aims to specify coverage details for nerve conduction studies,

Nerve conduction study results can assess the degree of demyelination and axon loss in the segments of the nerve studied.

Daman covers nerve conduction studies where medically necessary e.g.:

* To establish the diagnosis and prognosis of traumatic nerve lesions
* To establish the diagnosis and monitoring of neuromuscular junction
* disorders (e.g., myasthenia gravis).
* To establish the diagnosis of muscle disorders (e.g., myopathy).
* To diagnose generalized neuropathies
* To diagnose symptom-based complaints.
* Localization of compressive lesions (e.g., carpal tunnel syndrome).

# Scope

This adjudication rule highlights the medical necessity, coding and coverage rules for Nerve Conduction Studies (NCS) as per policy terms and conditions for all health insurance plans administered by Daman.

Nerve Conduction Studies (NCS) is performed to assess the integrity and diagnose diseases of the Peripheral nervous system. Pathological findings include conduction slowing, conduction block, no response, and/or low amplitude response. NCS results can assess the degree of demyelination and axon loss in the segments of the nerve studied.

- **Motor NCS:** Performed by applying electrical signal to various points along the course of a motor nerve while recording the electrical response from an appropriate muscle. Response parameters include amplitude, latency, configuration, and motor conduction velocity.

- **Sensory NCS**: Performed by applying electrical signal stimulation near a sensory nerve and recording the response from a distant site along the nerve. Response parameters include amplitude, latency, configuration, and motor conduction velocity.

- **Mixed NCS:** are performed by applying electrical stimulation near a nerve containing both motor and sensory fibres (a mixed nerve) and recording from a different location along that nerve that also contains both motor and sensory nerve fibres. Response parameters include amplitude, latency, configuration, and both sensory and motor conduction velocity.

# Adjudication Policy

## Eligibility / Coverage Criteria

**Medical indications:**

* + Diagnosis and prognosis of traumatic nerve lesions (e.g., spinal cord injury, trauma to nerves).
  + Diagnosis and monitoring of neuromuscular junction disorders (e.g., myasthenia gravis, myasthenic syndrome).
  + Diagnosis of muscle disorders (e.g., myositis, myopathy).
  + Diagnosis or confirmation of suspected generalized neuropathies (including uremic, metabolic, or immune) (e.g., amyotrophic lateral sclerosis, Guillain-Barré Syndrome, muscular dystrophy, post-polio syndrome).
  + Differential diagnosis of physical examination findings of sensory loss, weakness and/or muscle atrophy with no known etiology (e.g., diabetes, hypothyroidism, lupus, rheumatoid arthritis, etc.).
  + Differential diagnosis of symptom-based complaints e.g., pain in limb or joint, weakness, fatigue, cramps, twitching (fasciculations), disturbance in skin sensation or paresthesias (numbness or tingling) provided the clinical assessment supports the need for a study.
  + Localization of focal neuropathies or compressive lesions (e.g., Bell’s palsy of the facial nerve, carpal tunnel syndrome, cubital tunnel syndrome, tarsal tunnel syndrome, nerve root compression, neuritis, motor neuropathy, mononeuropathy, radiculopathy, unexplained peripheral neuropathy with pain of a neuropathic pattern.

**Important facts:**

* + Table 1: Reasonable Maximum Number of Nerve Conduction Studies (scope)
  + Table 2: Eligible Health professionals (Additional information section)
  + Table 3 Mutually Exclusive: Reject column 2 codes (Additional information section)
  + Table 4: CPT Codes with price and MUE (Additional information section)
  + CPT code 95905 is payable only once per limb studied when paired with diagnosis codes G56.00-G56.03 only and cannot be used in conjunction with any other nerve conduction codes.
  + NCS reports should document the nerves evaluated, the distance between the stimulation and recording sites, the conduction velocity, latency, and amplitude 1.
  + The CPT descriptor language, codes 95907-95913 describe one or more nerve conduction studies. For the purposes of coding, a single conduction study is defined as a sensory conduction test, a motor conduction test with or without an F-wave test, or an H-reflex test. Each type of nerve conduction study is counted only once when multiple sites on the same nerve are stimulated or recorded. The number of these separate tests should be added to determine which code to use, (for ICD 10 categorization and recommended studies please refer to table 5). It is inappropriate to count more than one unit for “inching” or studying the same nerve by moving the stimulating electrode closer to the recording electrode.
  + Minimum retesting time interval: Patients should be monitored every 2 weeks.

**Table 1:** Reasonable Maximum Number of Nerve Conduction Studies

|  |  |
| --- | --- |
| **Indications** | **Nerve conduction studies *(Total nerves studies, 95907-95913)*** |
| Carpal tunnel (unilateral) | 7 |
| Carpal tunnel (bilateral) | 10 |
| Radiculopathy | 7 |
| Mononeuropathy | 8 |
| Polyneuropathy/ Mononeuropathy multiplex | 10 |
| Myopathy | 4 |
| Motor Neuropathy (e.g., ALS) | 6 |
| Plexopathy | 12 |
| Neuromuscular junction | 4 |
| Tarsal tunnel syndrome (unilateral) | 8 |
| Tarsal tunnel syndrome (bilateral) | 11 |
| Weakness, Fatigue, Cramps, or Twitching (focal) | 7 |
| Weakness, Fatigue, Cramps, or Twitching (general) | 8 |
| Pain, Numbness, or Tingling (unilateral) | 9 |
| Pain, Numbness, or Tingling (bilateral) | 12 |

**Table 2: Eligible Health professionals**

|  |  |
| --- | --- |
| **Eligible Ordering clinician** | **Eligible Performing clinician** |
| Internal medicine | Registered technologist |
| Physical medicine and rehabilitation [PMR] physicians | Physical medicine and rehabilitation [PMR] physicians |
| Psychiatry | - |
| Pain medicine | - |
| Neurology | - |
| Orthopedic | - |
| Paediatric | - |

**Table 3 Mutually Exclusive:** Reject column 2 codes

|  |  |  |
| --- | --- | --- |
| **Column 1** | **Column 2** | **Decision** |
| 95913 | 95912 | Code 95912 is a column 2 code for 95913. |
| 95912 | 95911 | Code 95911 is a column 2 code for 95912. |
| 95913 | 95911 | Code 95911 is a column 2 code for 95913. |
| 95911 | 95910 | Code 95910 is a column 2 code for 95911. |
| 95912 | 95910 | Code 95910 is a column 2 code for 95912. |
| 95913 | 95910 | Code 95910 is a column 2 code for 95913. |
| 95910 | 95909 | Code 95909 is a column 2 code for 95910. |
| 95911 | 95909 | Code 95909 is a column 2 code for 95911. |
| 95912 | 95909 | Code 95909 is a column 2 code for 95912. |
| 95913 | 95909 | Code 95909 is a column 2 code for 95913. |
| 95909 | 95908 | Code 95908 is a column 2 code for 95909. |
| 95910 | 95908 | Code 95908 is a column 2 code for 95910. |
| 95911 | 95908 | Code 95908 is a column 2 code for 95911. |
| 95912 | 95908 | Code 95908 is a column 2 code for 95912. |
| 95913 | 95908 | Code 95908 is a column 2 code for 95913. |
| 95908 | 95907 | Code 95907 is a column 2 code for 95908. |
| 95909 | 95907 | Code 95907 is a column 2 code for 95909. |
| 95910 | 95907 | Code 95907 is a column 2 code for 95910. |
| 95911 | 95907 | Code 95907 is a column 2 code for 95911. |
| 95912 | 95907 | Code 95907 is a column 2 code for 95912. |
| 95913 | 95907 | Code 95907 is a column 2 code for 95913. |
| 95907 | 95905 | Code 95905 is a column 2 code for 95907. |
| 95908 | 95905 | Code 95905 is a column 2 code for 95908. |
| 95909 | 95905 | Code 95905 is a column 2 code for 95909. |
| 95910 | 95905 | Code 95905 is a column 2 code for 95910. |
| 95911 | 95905 | Code 95905 is a column 2 code for 95911. |
| 95912 | 95905 | Code 95905 is a column 2 code for 95912. |
| 95913 | 95905 | Code 95905 is a column 2 code for 95913. |

**Table 4: CPT Codes with price and MUE**

|  |  |  |  |
| --- | --- | --- | --- |
| **CPT Code** | **Code Description** | **Price**  **(AED)** | **MUE** |
| 95905 | Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report | 316 | NA |
| 95907 | Nerve conduction studies; 1-2 studies | 315 | 1 |
| 95908 | Nerve conduction studies; 3-4 studies | 408 | 1 |
| 95909 | Nerve conduction studies; 5-6 studies | 486 | 1 |
| 95910 | Nerve conduction studies; 7-8 studies | 641 | 1 |
| 95911 | Nerve conduction studies; 9-10 studies | 764 | 1 |
| 95912 | Nerve conduction studies; 11-12 studies | 848 | 1 |
| 95913 | Nerve conduction studies; 13 or more studies | 979 | 1 |

## Requirements for Coverage

* ICD and CPT codes must be coded to the highest level of specificity.
* Failure to submit, upon request or when requesting an informal review, a clinical history indication the need for testing will result in rejection of claim.

## Non-Coverage

* Nerve conduction studies are not covered for visitor plan.
* Will not be covered by Daman (for any plan) if it is not supported by a medically justified indication/diagnosis.
* For screening evaluation.

## Payment and Coding Rules

* Please apply DOH payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

# Denial Codes

|  |  |
| --- | --- |
| **Code** | **Code Description** |
| MNEC-003 | Service is not clinically indicated based on good clinical practice |
| MNEC-004 | Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities |
| MNEC-005 | Service /supply may be appropriate, but too frequent |
| CODE-010 | Activity / diagnosis inconsistency with clinician speciality |
| PRCE-002 | Payment is included in the allowance for another service |

# Appendices

## References

1. [*https://www.aanem.org/getmedia/65934187-d91e-4336-9f3c-50522449e565/Model-Policy.pdf*](https://www.aanem.org/getmedia/65934187-d91e-4336-9f3c-50522449e565/Model-Policy.pdf)
2. [*https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56619&ver=13&Cntrctr=All&UpdatePeriod=474&bc=AQAAFAAAAAAA&*](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56619&ver=13&Cntrctr=All&UpdatePeriod=474&bc=AQAAFAAAAAAA&)
3. [*https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57123&ver=18*](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57123&ver=18)
4. [*https://s3-us-west-2.amazonaws.com/images.provhealth.org/Providence-Images/PHP\_Nerve\_Conduction\_Studies\_CMS\_only.pdf*](https://s3-us-west-2.amazonaws.com/images.provhealth.org/Providence-Images/PHP_Nerve_Conduction_Studies_CMS_only.pdf)
5. [*https://s3-us-west-2.amazonaws.com/images.provhealth.org/Providence-Images/PHP\_Nerve\_Conduction\_Studies\_CMS\_only.pdf*](https://s3-us-west-2.amazonaws.com/images.provhealth.org/Providence-Images/PHP_Nerve_Conduction_Studies_CMS_only.pdf)
6. [*https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/nerve-conduction-studies*](https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/nerve-conduction-studies)
7. [*https://www.aapc.com/codes/all\_coding\_tools/home*](https://www.aapc.com/codes/all_coding_tools/home)
8. [*https://www.oxhp.com/secure/policy/neurophysiologic\_testing\_117.pdf*](https://www.oxhp.com/secure/policy/neurophysiologic_testing_117.pdf)

***other references***

1. [*https://www.aanem.org/getmedia/3275d71c-81dc-4b23-96a7-03173ecf8446/Recommended\_Policy\_EDX\_Medicine\_062810.pdf*](https://www.aanem.org/getmedia/3275d71c-81dc-4b23-96a7-03173ecf8446/Recommended_Policy_EDX_Medicine_062810.pdf)
2. [*https://downloads.cms.gov/medicare-coverage-database/lcd\_attachments/31346\_6/l31346\_neuro005\_cbg\_010112.pdf*](https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/31346_6/l31346_neuro005_cbg_010112.pdf)
3. [*http://www.symbiosisrcm.com/how-to-correctly-bill-nerve-conduction-studies/*](http://www.symbiosisrcm.com/how-to-correctly-bill-nerve-conduction-studies/)
4. [*http://bestpractice.bmj.com/best-practice/monograph/380/follow-up.html*](http://bestpractice.bmj.com/best-practice/monograph/380/follow-up.html)
5. [*http://bestpractice.bmj.com/best-practice/monograph/581/follow-up.html*](http://bestpractice.bmj.com/best-practice/monograph/581/follow-up.html)
6. [*http://emedicine.medscape.com/article/1170337-treatment#d20*](http://emedicine.medscape.com/article/1170337-treatment#d20)
7. [*http://www.aanem.org/Advocacy/EMG-Laws-by-State*](http://www.aanem.org/Advocacy/EMG-Laws-by-State)
8. [*http://www.aanem.org/getmedia/1e53beb2-987d-4f06-b091-ebe56148a8b9/Who-is-Qualifed-to-Practice-EDX-2012.pdf*](http://www.aanem.org/getmedia/1e53beb2-987d-4f06-b091-ebe56148a8b9/Who-is-Qualifed-to-Practice-EDX-2012.pdf)
9. [*http://acewm.org/wp-content/uploads/2012/02/ACE\_Minimum\_Standards\_Policy\_Mar\_31\_2011.pdf*](http://acewm.org/wp-content/uploads/2012/02/ACE_Minimum_Standards_Policy_Mar_31_2011.pdf)
10. [*http://www.neurology.ae/test\_details.php?ID=4*](http://www.neurology.ae/test_details.php?ID=4)
11. [*http://www.symbiosisrcm.com/how-to-correctly-bill-nerve-conduction-studies/*](http://www.symbiosisrcm.com/how-to-correctly-bill-nerve-conduction-studies/)

## Revision History

|  |  |
| --- | --- |
| **Date** | **Change(s)** |
| 14.03.2023 | Creation of Adjudication Guideline-External Instruction Template. |
| 09-05-2023 | Release of V2.0   * *Closure updates* * *CPT MUE* * *CPT Mutually exclusive* * *Updated Reasonable Maximum Number of Nerve Conduction Studies* * *New CPT 2018 codes added* |

**Disclaimer**

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter “Daman”). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman’s express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association (“AMA”) and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.